IFPMA and WADA Joint Declaration on Cooperation in the Fight against Doping in Sport
7 July 2010
This event has now passed. To browse our upcoming events click here.
The IFPMA and the World Anti-Doping Agency (WADA) signed a Joint Declaration on Cooperation in the Fight against Doping in Sport.
The Declaration aims to facilitate voluntary cooperation between WADA and IFPMA member companies, to identify medicinal compounds with doping potential, minimize misuse of medicines still in development, improve the flow of relevant information and facilitate development of detection methods in the context of the fight against doping in sport.
In a written statement, the Hon. John Fahey said: “We are very pleased that the IFPMA will be cooperating actively with WADA in the fight against doping in sport. As soon as a reliable method to detect a particular doping compound in athletes is developed, dopers start looking for a new compound which might enhance performance. Working closely with pharmaceutical companies to identify new potential doping compounds before they enter clinical trials should facilitate much faster development of detection methods, which will benefit clean athletes worldwide.”
Mr. Haruo Naito commented: “IFPMA members recognize that medicines may be misused to enhance sporting performance, thereby creating unfair competition and putting athletes’ health and even lives at risk. With pharmaceutical companies working hand-in-hand with WADA, more resources will be brought to bear on the scourge of doping, leading to cleaner sports and healthier athletes.”
The Declaration has been inspired by a number of successful bilateral collaborative exercises between WADA and individual pharmaceutical companies, including Merck & Co., Inc. and Roche.
Dr. Olivier Rabin has been WADA’s Science Director since September 2002.
He has established an international reputation as an expert in pharmaceutical
research and development.
Prior to joining WADA, Dr. Rabin worked for more than seven years for
Beaufour-IPSEN Pharma, in the United Kingdom and in France, in the fields of
research and business development. In this capacity, he was responsible for
the international development of new medicines and led scientific and medical
teams for in-depth assessment of projects.
Prior to his work at Beaufour-IPSEN, Dr. Rabin was a principal investigator in
research in pharmacology and toxicology for government organizations,
including four years spent at the National Institutes of Health in the United
States, where he was responsible for a cerebral ischemia program and the
development of pharmacological strategies for brain neuroprotection. He also
worked at the Institut National de la Santé et de la Recherche Médicale in
Dr. Rabin has a PhD in fundamental and applied toxicology and a degree in
biomedical engineering. He is the author of numerous scientific publications.
Dr Yves Juillet is the Chairman of the IFPMA Regulatory Policy and Technical
He is a specialist in internal medicine, cardiology and pharmacology, and is at
present Senior Advisor to LEEM (the Association of Pharmaceutical
Companies in France).
Prior to this appointment he was Director of Public Affairs of Aventis, Director
of Pharmaceutical and Public Affairs of Hoechst Marion Roussel, Inspector
General of Roussel Uclaf, Vice President for Licensing, Medical and
Regulatory Affairs of the Jouveinal Group, Deputy Managing Director and
Director of Scientific and Technical Affairs of SNIP (French Manufacturers
Association) and Department Head at the Broussais Hospital in Paris.
For seven years, Dr Juillet was a Member of the official Registration
Committee (AMM), Transparency and Post Marketing Committees of the
French Health Ministry, where he represented Industry. He was also a
member of the Board and the Executive Board of the Pharmaceutical Industry
Association in France.
He was Chair of the EFPIA Scientific Technical and Regulatory Policy
Committee for 10 years. He was a Member of the ICH Steering Committee
and Co-Chair of the ICH GCG.
He is a Member of the French Académie Nationale de Pharmacie and corresp
Member of the Académie de Médecine.
He is President Elect of the Drug Information (DIA)
David Howman commenced work for WADA as chief operating officer/special
counsel in March 2003, and took over the position of director general in August
Previously, he was a member of WADA’s Foundation Board, representing
Oceania, and the chair of the WADA Legal Working Group. In addition, he
served as the chair of the Independent Observer Team at the Winter Olympic
Games in Salt Lake City 2002, and the deputy chair of the Independent
Observer Team to the Sydney Olympic Games in 2000.
David Howman comes from Wellington, New Zealand, where he practiced as a
barrister specializing in Sports Law. He was chairman of the New Zealand
Sports Drug Agency between 2000 and 2003 and, previously, its counsel. He
was instrumental in writing the legislation for the Agency and appeared as its
counsel at several court hearings.
David Howman served as president of New Zealand Tennis and commissioner
for New Zealand Rugby for a number of years. He represented many
prominent New Zealand sportsmen in various activities and contractual areas.
Highly ranked as a junior tennis player, David Howman was a member of the
New Zealand Junior Davis Cup squad, and represented Victoria University in
Rugby. He continues to exercise regularly and counts rugby, tennis, golf, and
running among his sporting interests.
Mr. Haruo Naito has been President and CEO of Eisai Co., Ltd. of Japan since 1988 and instituted the company’s new strategic orientation focusing on active participation in numerous facets of human health care delivery systems. Under his leadership, Eisai has established a global strategic research network, consisting of research centers in the USA, Europe and Asia. In addition, Eisai now has business activities in some forty countries throughout the world. Mr. Naito currently serves on Northwestern University’s Kellogg Advisory Board and Duke University’s Fuqua Board of Visitors. He also serves as Vice President of the International Pharmaceutical Manufacturers & Associations (IFPMA). In April 1999, he was awarded an honorary CBE by the United Kingdom in recognition of his long-standing efforts in strengthening UK – Japan relations.